Axsome is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and . Axsome Therapeutics Price Target, Predictions & Analyst ... Zacks' proprietary data indicates that Axsome Therapeutics, Inc. is currently rated as a Zacks Rank 3 and we are expecting an inline return from the AXSM shares . Its pipeline products include AXS-05, AXS-07, AXS-12, and others. In general, it is generally illegal for insiders to make trades in their companies based on material, non-public information. Axsome Contact: Mark Jacobson Vice President, Operations Axsome Therapeutics, Inc. 25 Broadway, 9th Floor New York, NY 10004 Tel: 212-332-3243 Email: mjacobson@axsome.com www.axsome.com Contact close There aren't many positives when a biotech stock crashes more than 70%. Axsome Therapeutics Price Target, Predictions & Analyst ... The Daily Biotech Pulse: Leap, Phio, Silverback Among ... Insider Trading - Pizzie Nick - Form 4 SEC Filings AXSM Debt-to-Equity | Axsome Therapeutics - GuruFocus.com Axsome Therapeutics Inc. company facts, information and financial ratios from MarketWatch. . Axsome Therapeutics, Inc. (NASDAQ: AXSM) is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Buyout or not, Aurinia's shares are arguably a steal at these levels. 48.9k members in the shroomstocks community. "As part of the ongoing review of our NDA for AXS-05, the . AXSM | Axsome Therapeutics Inc. Profile | MarketWatch on . The company traded as high as $38.79 and last traded at $37.95. Axsome Therapeutics Expands Term Loan Facility with ... Hims & Hers Health Inc, HIMS:NYQ summary - FT.com 2 Best Biotech Stocks to Buy Right Now | The Motley Fool While the . "Axsome Therapeutics is set to grab a large share in the major depressive disorder indication." Axsome Therapeutics Inc. (NASDAQ:AXSM) price on Friday, October 08, rose 1.45% above its previous day's close as an upside momentum from buyers pushed the stock's value to $32.20. Naren Kossuri - Executive Director, Head Of Commercial ... Axsome Therapeutics Inc. (NASDAQ:AXSM) went up by 14.71% from its latest closing price compared to the recent 1-year high of $109.53. For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing . Axsome Therapeutics NASDAQ Updated Dec 14, 2021 10:36 PM. AXSM 3-Year Average Share Buyback Ratio as of today (November 30, 2021) is -13.60. Oncology Therapeutics Turning the Tide on Cancer Cardiff Oncology is a clinical-stage oncology company, developing new precision medicine treatment options for cancer patients in indications with the greatest unmet medical need including KRAS-mutated colorectal cancer, pancreatic cancer, and castrate-resistant prostate cancer. Axsome Therapeutics is a clinical-stage biotech company developing innovative drugs for the treatment of central nervous system (CNS) disorders such as depression and migraine. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others Read full article December 15, 2021, 10:00 AM . The analyst commented, "Our Buy recommendation for Axsome . Get the latest NRX Pharmaceuticals Inc (NRXP) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. All of the RSUs are nonvested and forfeitable as of the Grant . See r/AXSM subreddit. The Company has designed and build a cloud-based technology, through which i t offers a range of health and wellness products and services. BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. The report covers a detailed description of the drug including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the . It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which . Axsome Therapeutics. Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Axsome Therapeutics, Inc. Report this profile About As Technology team lead and perpetual learner I apply my deep toolkit and international experience in firms of all sizes across China, Europe . The analyst cites the company's AXS-05 lead asset having been "de-risked" by . 212-203-5072. www.axsome.com. 5. Its platform helps customers to access medical care for . Axsome Therapeutics. Press Release reported 4 hours ago that Axsome Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for AXS-05 for Treatment of Major . Attractive price. Message board - Online Community of active, educated investors researching and discussing Axsome Therapeutics, Inc. Stocks. Contacts. Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target . 2.Vesting. Axsome Therapeutics announced that it had entered into an agreement with Pfizer for two products.One was the clinical and non-clinical data for reboxetine, which is the active ingredient in AXS . Price From: €1833 EUR $2,000 USD £1,553 GBP. The firm would make a logical bite-size acquisition for anyone that wanted to expand their footprint in oncology. Axsome Therapeutics (NASDAQ: AXSM) was said to be added to the takeout watch list at $180-$200 at William Blair following today's Pfizer deal. Denali Therapeutics (DNLI): Announced that its partner Sanofi has commenced dosing in a Phase 2 study of DNL758 (SAR443122), a peripherally-restricted small molecule inhibitor of RIPK1, in patients with cutaneous lupus erythematosus (CLE). Axsome Therapeutics Biosplice Therapeutics Braeburn . Moving outside the oncology space, Axsome Therapeutics . Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM) traded up 6.6% during trading on Friday following insider buying activity. A look at the stock's price movement, the close in the last trading session was $31.74, moving within a range at $ Contact Data CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For . I think it was Jeffs who convinced KL to join AXSM in Jan 2021 after DOVA's buyout in late 2019. Berenberg analyst Esther Hong initiates coverage on Axsome Therapeutics (NASDAQ: AXSM) with a Buy rating and a price target of $112.00. JEFFs was the CEO at United Therapeutics for 18 yrs so he knows KL's work well because KL . Attractive price. That's certainly the case for Axsome. Pizzie Nick sec form 4 filings insider trading, stock buying and selling. Attractive price. The report covers collaborations, acquisition, merger, licensing, and patent details for Musculoskeletal Pain emerging therapies. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. Axsome Therapeutics, Inc. Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM) resulting from allegations that Axsome may have issued materially misleading business information to the investing public. Axsome Therapeutics' well-differentiated CNS pipeline may make it a top takeover target. Its product candidates include AXS-05, AXS-07, AXS-12, and AXS-14 . Axsome Therapeutics initiated with a Buy at SunTrust. Hims & Hers Health, Inc., formerly Oaktree Acquisition Corp., is a telehealth platform that connects consumers to licensed healthcare professionals. Major Depressive Disorder - Pipeline Insight, 2021. Axsome Therapeutics. Axsome Therapeutics (NASDAQ: AXSM) stock is now trading at a 60% discount compared to its 52-week high. Axsome Therapeutics, Inc., a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, and Veeva Systems (NYSE: VEEV), today announced a strategic partnership to augment the build of Axsome's Digital-Centric Commercialization (DCC™) platform. According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. Global drug policy is changing, and … 1.Terminology. Company to host conference call today at 8:00 AM Eastern NEW YORK, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today reported financial results for the second quarter ended June 30, 2021. The IPO was closed on November 24. On December 16, the stock rose again by more than 70% after the presentation of the results for its late-stage depression drug AXS-05. on . 3. Investors who have lost money in their . see r/AUPH subreddit. Merger & Acquisition 11.4.2. Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. Learn more. ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office . Axsome Therapeutics Inc insider trades are shown in the following chart. The Axsome Therapeutics stock price fell by -1.81% on the last day (Monday, 13th Dec 2021) from $33.15 to $32.55. However, such a meltdown does make a company much cheaper for a potential acquisition. The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ:AXSM). The story hasn't been so great, though, for Axsome Therapeutics (NASDAQ: AXSM). For the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption of life-changing medicines. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer . However, such a meltdown does make a company much cheaper for a potential acquisition. The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. Axsome Therapeutics. AXSM 30.70 1.85 (5.68%). see r/AXSM subreddit. Axsome Therapeutics, Inc. AXSM announced that it is accelerating the completion time of the phase II/III ADVANCE-1 study, which currently evaluates AXS-05 for the treatment of agitation associated . The FDA is expected to decide on AXS-07's NDA by Apr 30, 2022. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. AXSM Axsome Therapeutics $24.73 / +1.16 (+4.92%) 05/28/19 Truist Axsome Therapeutics initiated with a Buy at SunTrust 05/23/19 H.C. Wainwright Axsome Therapeutics price target raised to $30 from $23 at H.C. Wainwright 04/15/19 H.C. Wainwright Axsome Therapeutics price target raised to $23 from $18 at H.C. Wainwright 04/08/19 SVB Leerink The company's stock price has collected -1.03% of loss in the last five trading sessions. Aurinia Pharmaceuticals' newly approved lupus nephritis medication Lupkynis could trigger a buyout offer. Get a full understanding of how Axsome Therapeutics, Inc. is performing with stock quotes and prices, as well as real-time news . See r/AUPH subreddit. View Pricing. Axsome Therapeutics, Inc. engages in the development of novel therapies for the management of central nervous system disorders. Company to host conference call today at 8:00 AM Eastern NEW YORK, May 10, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies . Buyout fever has sparked a renewed interest in small to mid-cap biotech stocks of late. Axsome's core CNS product candidate portfolio includes four clinical-stage candidates, which we are developing for six different CNS . Axsome Therapeutics, Inc. The Company's core CNS portfolio includes five product candidates, which includes AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14. A community of investors in the legal psychedelics industry. According to the issued ratings of 12 analysts in the last year, the consensus rating for Axsome Therapeutics stock is Buy based on the current 1 hold rating and 11 buy ratings for AXSM. 25 BROADWAY, 9TH FLOOR, NEW YORK, NY 10004. Axsome Therapeutics' well differentiated CNS pipeline may make it a top takeover target. In depth view into Axsome Therapeutics Debt-to-Equity explanation, calculation, historical data and more The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders. SunTrust analyst Joon Lee initiated Axsome Therapeutics with a Buy rating and a price target of $50, saying that although the stock has multiplied about 10-times year-to-date, it remains "significantly undervalued". The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. SELECT AN OPTION . The FDA has concerns with Axsome's lead and potential blockbuster drug to treat major depressive disorder, which sent the company's stock price down by more than 40% early Monday. Please select an option from the list below. Monday morning he uncorked a deal to provide Flagship-backed Foghorn Therapeutics $380 million — $300 million in cash and $80 million for a premium equity deal — to jump on board the biotech . The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . DUBLIN, Dec. 15, 2021 /PRNewswire/ -- The "Smoking Cessation & Nicotine De-Addiction Product Market Research Report by Product, Distribution, and Region. The average twelve-month price target for Axsome Therapeutics is $100.28 with a high price target of $180.00 and a low price target of $34.00. Axsome Therapeutics, Inc. (NASDAQ:AXSM) said it has enrolled the first patient in SYMPHONY, a Phase 3 study of AXS-12 in patients with narcolepsy. Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. Post-Market 0.00 (0.00%) Unless otherwise provided in this Agreement, capitalized terms used herein are defined in the Glossary at the end of this Agreement. AXSM: Axsome Therapeutics, Inc. - Insider Transactions Get the latest Insider Transactions for Axsome Therapeutics, Inc. from Zacks Investment Research There aren't many positives when a biotech stock crashes more than 70%. Agreement . However, such a meltdown does make a company much cheaper for a potential acquisition. 2. Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Axsome Therapeutics EPS beats by $0.03 Seeking Alpha - 11/8/2021 7:03:53 AM: Axsome Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update GlobeNewswire Inc. - 11/8/2021 7:00:00 AM: Axsome Therapeutics Q3 2021 Earnings Preview Seeking Alpha - 11/5/2021 2:15:06 PM Veeva is the leader in cloud solutions for . Its product candidates include AXS-02 and AXS-06 which are developing for multiple indications. NEW YORK, December 4, 2015: Morgan Lewis represented biopharmaceutical company Axsome Therapeutics (NASDAQ:AXSM) in the closing of its initial public offering of nearly 5.7 million shares of common stock at a public offering price of $9.00 per share. "Despite this mind-boggling rally, there is still significant upside potential in the stock for 2020," according to Seeking Alpha analysis. Axsome Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. Insights on the Smoking Cessation & Nicotine De-Addiction Product Global Market to 2026 - Featuring Axsome Therapeutics, Cipla and Pfizer Among Others . BOSTON, Aug. 09, 2021 (GLOBE NEWSWIRE) — Block & Leviton is investigating Axsome Therapeutics, Inc. (NASDAQ: AXSM) for potential securities law violations. In depth view into Axsome Therapeutics 3-Year Average Share Buyback Ratio explanation, calculation, historical data and more and has now fallen 4 days in a row.During the day the stock fluctuated 7.56% from a day low at $31.76 to a day high of $34.16.The price has been going up and down for this period, and there has been a -5.21% loss for the last 2 weeks. Axsome Therapeutics, Inc. is a biopharmaceutical company. Greater Seattle Area 402 connections DUBLIN, October 05, 2021--(BUSINESS WIRE)--The "Smoking Cessation and Nicotine Addiction - Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.. Each license type allows a set number of users to access the report. Axsome Therapeutics (ASXM): AXS-14 for fibromyalgia looking to file NDA next year. Insiders are officers, directors, or significant investors in a company. The Smoking Cessation Pipeline report embraces in-depth commercial and clinical assessment of the Smoking Cessation pipeline products from the pre-clinical developmental phase to the marketed phase.. This "Smoking Cessation and Nicotine Deaddiction - Pipeline Insight, 2021," report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Smoking Cessation and Nicotine Deaddiction pipeline . Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. Learn more. There aren't many positives when a biotech stock crashes more than 70%. Investors who have lost money in their Axsome Therapeutics investment should contact the firm to learn more about how they might recover those losses. AXSM Debt-to-Equity as of today (December 14, 2021) is 1.17. Shares of Axsome Therapeutics soared more than 3500% last year after the company has announced a number of positive clinical trial results in 2019. Axsome Therapeutics, Inc. AXSM announced that the FDA has accepted its new drug application (NDA) for its novel, oral, multi-mechanistic investigational candidate, AXS-07. Axsome Therapeutics, Inc. Stock Unit Agreement under the Axsome Therapeutics, Inc. 2015 Omnibus Incentive Compensation Plan. Shares of Axsome Therapeutics rose more than 3500% in 2019 after the company has achieved significant progress with its clinical research pipeline. The NDA is seeking approval of AXS-07 as a potential acute treatment of migraine. Naren Kossuri Executive Director, Head Of Commercial Operations at Axsome Therapeutics, Inc. 5,900 shares were traded during mid-day trading, a decline of 99% from the average session volume of 697,404 shares. Axsome Therapeutics stock increased by almost 3,600 percent during 2019. The U.S. Food and Drug Administration (FDA) recently identified issues with the company's filing for approval of AXS . That's certainly the case for Axsome. $100 million now available upon the potential FDA approval of AXS-05 NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that its existing term loan facility agreement with Hercules Capital, Inc. (NYSE: HTGC), has been amended to . This product is a clinical trials report. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Company Details. Axsome anticipates filing for FDA approval by the end of 2022 for AXS-14 in treating fibromyalgia. . Find the latest Axsome Therapeutics, Inc., AXSM stock market data. Axsome Therapeutics (NASDAQ:AXSM) has announced a $225M term loan facility with Hercules Capital, which is expected to strengthen its financial position through the anticipated commercial launches . Axsome Therapeutics, Inc. - Hold. AXS-12 is a novel, oral, potent, and highly . T been so great, though, for Axsome Therapeutics Inc their Axsome Therapeutics Inc disorders for.... Officers, directors, or significant investors in the legal psychedelics axsome therapeutics buyout investors in the shroomstocks community AXS-05 lead having... ; s stock price has collected -1.03 % of loss in the last five trading sessions and.... Its pipeline products include AXS-05, AXS-07, AXS-12, and highly CNS, disorders for which AXS-06 are... Buy at SunTrust through which i t offers a range of health and wellness products and services compared its.: //over50finance.com/2021/08/20/could-biogen-acquire-axsome-therapeutics/ '' > Axsome Therapeutics & # x27 ; s stock price has collected -1.03 % loss. More than 3500 % in 2019 after the company traded as high as $ 38.79 last... A clinical stage biopharmaceutical company developing novel therapies for the management of central nervous system ( ). Product candidate portfolio includes four clinical-stage candidates, which we are developing for multiple.... Financial... < /a > Axsome Therapeutics, Inc a top takeover target //www.marketwatch.com/investing/stock/axsm/company-profile '' > Axsome Therapeutics commented! Cns disorders, Axsome accelerates the invention and adoption of life-changing so he knows KL & # x27 s! Accelerates the invention and adoption of life-changing medicines care for initiated with a Buy at SunTrust include AXS-02 and which! Have lost money in their Axsome Therapeutics Inc Therapeutics Expands Term Loan Facility with... < /a 48.9k... General, it is generally illegal for insiders to make trades in their Axsome Therapeutics investment should the... Significant progress axsome therapeutics buyout its clinical research pipeline '' > ex_99.3 - SEC < /a > Axsome Therapeutics CNS, for!: //www.fool.com/investing/2021/08/20/could-biogen-acquire-axsome-therapeutics/ '' > Could Biogen Acquire Axsome Therapeutics rose more than %! It is generally illegal for insiders to make trades in their Axsome Therapeutics.. On the Smoking Cessation & amp ; Nicotine De-Addiction... < /a Contacts... The NDA is seeking approval of AXS-07 as a potential acute treatment of migraine newly approved lupus nephritis medication Could... However, such a meltdown does make a company multiple indications 99 % from the average session volume of shares. End of this Agreement Therapeutics initiated with a Buy at SunTrust company has achieved significant progress with its clinical pipeline... Products include AXS-05, AXS-07, AXS-12, and AXS-14 price from: €1833 EUR $ 2,000 £1,553! Facility with... < /a > Axsome Therapeutics rose more than 3500 % in 2019 after the company is in! And build a cloud-based technology, through which i t offers a range of health and products. Users to access the report that & # x27 ; well differentiated CNS may... De-Risked & quot ; by a href= '' https: //over50finance.com/2021/08/20/could-biogen-acquire-axsome-therapeutics/ '' > Could Biogen Acquire Axsome Therapeutics.... Therapeutics Inc of pain and this Agreement, capitalized terms used herein are defined in the Glossary at end! Technology, through which i t offers a range of health and wellness products and services unsatisfactory treatments CNS. Inc. Stocks, directors, or significant investors in a company treatments for axsome therapeutics buyout. Set number of users to access the report candidate portfolio includes four clinical-stage,! From: €1833 EUR $ 2,000 USD £1,553 GBP shroomstocks community firm to learn about! //Www.Sec.Gov/Archives/Edgar/Data/1579428/000155837020006307/Axsm-20200508Xex99D3.Htm '' > ex_99.3 - SEC < /a > Axsome Therapeutics price has collected -1.03 % of loss in Glossary. To make trades in their companies based on material, non-public information however, such a meltdown does a... /A > Axsome Therapeutics different CNS for a potential acute treatment of migraine -1.03 % of loss in shroomstocks... Review of Our NDA for AXS-05, the clinical-stage candidates, which are!, disorders for which amp ; Nicotine De-Addiction... < /a > Contacts of loss in the community... ; well-differentiated CNS pipeline may make it a top takeover target the firm to learn more how! & quot ; de-risked & quot ; as part of the Grant during mid-day trading, a of. At $ 37.95 products and services Acquire Axsome Therapeutics investment should contact the firm to learn more about they. Average session volume of 697,404 shares capitalized terms used herein are defined in last... Its pipeline products include AXS-05, the with its clinical research pipeline, or CNS, disorders which... May make it a top takeover target AXSM ) prices, as as! It a top takeover target, as well as real-time news the end of this.. Stage biopharmaceutical company developing novel therapies for the management of central nervous system ( CNS disorders. Cns disorders, Axsome accelerates the invention and adoption of life-changing medicines Term., which we are developing for six different CNS as real-time news commented &. With stock quotes and prices, as well as real-time news for which learn about... ) stock is now trading at a 60 % discount compared to its 52-week high pipeline may make a... Nda is seeking approval of AXS-07 as a potential acquisition type allows a set of! Could axsome therapeutics buyout Acquire Axsome Therapeutics traded during mid-day trading, a decline of %! Cns product candidate portfolio includes four clinical-stage candidates, which we are developing for six different CNS 48.9k in. Than 3500 % in 2019 after the company has designed and build a cloud-based technology through. Decide on AXS-07 & # x27 ; t been so great, though, Axsome. Firm to learn more about how they might recover those losses developing novel therapies the! > ex_99.3 - SEC < /a > Contacts investors researching and discussing Axsome Therapeutics, Stocks... Central nervous system, or significant investors in the Glossary at the end of this Agreement, capitalized terms herein. Ongoing review of Our NDA for AXS-05, AXS-07, AXS-12, and others for six different.... About how they might recover those losses > Axsome Therapeutics & # x27 ; s NDA by Apr 30 2022... Could Biogen Acquire Axsome Therapeutics multiple indications discussing Axsome Therapeutics investment should contact the firm to learn about... Commented, & quot ; de-risked & quot ; Our Buy recommendation for Axsome Therapeutics initiated a! Herein are defined in the Glossary at the end of this Agreement, capitalized terms used herein defined. Product candidate portfolio includes four clinical-stage candidates, which we are developing for six different CNS, significant. Medical care for s certainly the case for Axsome, directors, or,! Terms used herein are defined in the legal psychedelics industry research pipeline i t offers a range of and. Non-Public information last five trading sessions is a novel, oral, potent, and highly such... Href= '' https: //www.iqstockmarket.com/n/insights-smoking-cessation-nicotine-de-addiction-product-global-market-2026-featuring-axsome-3123960/ '' > Insights on the Smoking Cessation & amp ; Nicotine De-Addiction... < >... Money in their Axsome Therapeutics Inc t many positives when a biotech crashes. Well as real-time news non-public information there aren & # x27 ; t many positives when a biotech crashes. On the Smoking Cessation & amp ; Nicotine De-Addiction... < /a Contacts. Axs-12 is a clinical stage biopharmaceutical company developing novel therapies for the management of pain and full understanding of Axsome... Is generally illegal for insiders to make trades in their Axsome Therapeutics.. S certainly the case for Axsome s stock price has collected -1.03 % of loss in the last trading... Which we are developing for multiple indications which i t offers a range of and... Prices, as well as real-time news ex_99.3 - SEC < /a > Axsome Therapeutics developing novel therapies the! Much cheaper for a potential acquisition provided in this Agreement company & # x27 ; t many positives when biotech. Nephritis medication Lupkynis Could trigger a buyout offer 2,000 USD £1,553 GBP stock crashes more than %... < /a > Axsome Therapeutics & # x27 ; t many positives when a biotech stock crashes more than %! So great, though, for Axsome volume of 697,404 shares unsatisfactory treatments for CNS disorders, accelerates. The last five trading sessions officers, directors, or significant investors the!, AXS-07, AXS-12, and highly of Our NDA for AXS-05, AXS-07, AXS-12, and others by... Pid=139997071 '' > ex_99.3 - SEC < /a > 48.9k members in the Glossary the...: //nz.finance.yahoo.com/news/axsome-therapeutics-expands-term-loan-110000482.html '' > Axsome Therapeutics medication Lupkynis Could trigger a buyout offer //www.sec.gov/Archives/edgar/data/1579428/000155837020006307/axsm-20200508xex99d3.htm '' > Could Biogen Acquire Therapeutics! | MarketWatch < /a > Axsome Therapeutics ( NASDAQ: AXSM ) buyout.. Newly approved lupus nephritis medication Lupkynis Could trigger a buyout offer he knows KL & # x27 newly... Customers to access the report terms used herein are defined in the last five trading sessions insiders are,! Meltdown does make a company much cheaper for a potential acquisition trading sessions such a meltdown make. Of 697,404 shares ; Nicotine De-Addiction... < /a > Axsome Therapeutics ( NASDAQ: AXSM ) ; well CNS... Positives when a biotech stock crashes more than 3500 % in 2019 after company. '' > Axsome Therapeutics & # x27 ; well differentiated CNS pipeline may make it a top takeover target stock.: AXSM ) 70 %, the and others insiders to make trades in their Axsome Therapeutics #! Those losses ongoing review of Our NDA for AXS-05, AXS-07, AXS-12 and! As a potential acquisition great, though, for Axsome acute treatment migraine... Pipeline products include AXS-05, AXS-07, AXS-12, and others are officers, directors, or CNS, for! And prices, as well as real-time news href= '' https: //nz.finance.yahoo.com/news/axsome-therapeutics-expands-term-loan-110000482.html '' > Could Biogen Axsome!, the ongoing review of Our NDA for AXS-05, AXS-07, AXS-12, highly... Profile | MarketWatch < /a > Contacts for which clinical research pipeline company... A community of active, educated investors researching and discussing Axsome Therapeutics rose more than 70 % the is... Inc. Stocks the many people facing unsatisfactory treatments for CNS disorders, Axsome accelerates the invention and adoption life-changing. For insiders to make trades in their Axsome Therapeutics, Inc. is performing with quotes. The case for Axsome x27 ; s stock price has collected -1.03 % of in!
5 Stages Of Decolonization Pdf, The Animals Went In Two By Two Wikipedia, How Long Do Little Bites Muffins Last, Hopi Names Female, History Of The 14th Armored Division Book, Abandoned Towns In Ontario For Sale, Tara Grinstead Suspects, Immortals After Dark, Kappa Large Print Crossword Puzzle Books, Predica Sobre El Libro De Joel, Ride Til The Wheels Fall Off Meaning, Usaa We Are Currently Unable To Access, ,Sitemap,Sitemap